Single-center Outcomes After Liver Transplantation With SARS-CoV-2–Positive Donors: An Argument for Increased Utilization DOI Creative Commons
Ashton A. Connor, Max W. Adelman, Constance M. Mobley

et al.

Transplantation Direct, Journal Year: 2024, Volume and Issue: 10(4), P. e1590 - e1590

Published: March 7, 2024

Background. The COVID-19 pandemic has led to an increase in SARS-CoV-2–test positive potential organ donors. benefits of life-saving liver transplantation (LT) must be balanced against the risk donor-derived viral transmission. Although emerging evidence suggests that use COVID-19–positive donor organs may safe, granular series thoroughly evaluating safety are still needed. Results 29 consecutive LTs from donors at a single center presented here. Methods. A retrospective cohort study LT recipients between April 2020 and December 2022 was conducted. Differences (n = total; 25 index, 4 redo) COVID-19–negative 472 454 18 deceased grafts were compared. Results. significantly younger ( P 0.04) had lower kidney profile indices than Recipients older but otherwise similar negative Donor SARS-CoV-2 infection status not associated with overall survival (hazard ratio, 1.11; 95% confidence interval, 0.24-5.04; 0.89). There 3 deaths among No death seemed virally mediated because there no qualitative association peri-LT antispike antibody titers, post-LT prophylaxis, or variants. Conclusions. utilization decreased recipients. suggestion transmission recipient. results this large single-center suggest used safely expand pool.

Language: Английский

Update on Covid-19: vaccines, timing of transplant after COVID-19 infection and use of positive donors DOI
C Boutin, Maha Alamri, Michael G. Ison

et al.

Current Opinion in Organ Transplantation, Journal Year: 2023, Volume and Issue: 28(2), P. 76 - 84

Published: Feb. 15, 2023

Purpose of review SARS-CoV-2 resulted in a global pandemic that had chilling effect on transplantation early the and continues to result significant morbidity mortality transplant recipients. Over past 2.5 years, our understanding clinical utility vaccination mAbs prevent COVID-19 solid organ (SOT) recipients has been studied. Likewise, approach donors candidates with better understood. This will attempt summarize current these important topics. Recent findings Vaccination against is effective reducing risk severe disease death among patients. Unfortunately, humoral and, lesser extent, cellular immune response existing vaccines reduced SOT compared healthy controls. Additional doses vaccine are required optimize protection this population still may be insufficient those who highly immunosuppressed, receiving belatacept, rituximab other B-cell active mAbs. Until recently, were options for prevention but markedly less recent omicron variants. SARS-CoV-2-infected can generally used nonlung, nonsmall bowel transplants unless they have died acute or COVID-19-associated clotting disorders. Summary Our require three-dose mRNA adenovirus-vector one dose optimally protected initially; then need receive bivalent booster 2+ months after completing their initial series. Most utilized as donors.

Language: Английский

Citations

5
Posttransplant outcomes and trends in use of COVID-19-positive deceased donor liver transplantation DOI
Roy Wang, Samir Abu‐Gazala, Nadim Mahmud

et al.

Liver Transplantation, Journal Year: 2023, Volume and Issue: 29(10), P. 1129 - 1133

Published: May 10, 2023

1Department of Medicine, Hospital the University Pennsylvania, Philadelphia, USA 2Division Transplant Surgery, 3Division Gastroenterology and Hepatology, 4Department Corporal Michael J. Crescenz VA Medical Center, 5Leonard David Institute Health Economics, Pennsylvania Perelman School 6Center for Clinical Epidemiology Biostatistics, Department & Informatics, Abbreviations: DDLT, deceased donor liver transplantation; SHR, sub HR. Correspondence Nadim Mahmud, Division Gastroenterology, USA. Email: [email protected]

Language: Английский

Citations

5
Early outcomes of lung transplantation with lung allografts from coronavirus disease 2019 (COVID-19)–positive donors DOI
Jae Hyun Jeon, Takashi Harano, Jack Rodman

et al.

Journal of Thoracic and Cardiovascular Surgery, Journal Year: 2023, Volume and Issue: 167(6), P. 1955 - 1964.e3

Published: Aug. 23, 2023

Language: Английский

Citations

5
COVID-19 in patients with liver disease and liver transplant: clinical implications, prevention, and management DOI Creative Commons

Gabriel Perreault,

Charlotte K. Ching, Yael R. Nobel

et al.

Therapeutic Advances in Gastroenterology, Journal Year: 2023, Volume and Issue: 16

Published: Jan. 1, 2023

The coronavirus disease 2019 (COVID-19) pandemic has had enormous implications for the care of patients with chronic liver (CLD), cirrhosis, and transplant (LT). Clinical outcomes COVID-19 vary in CLD cirrhosis compared to healthy controls, LT without LT. Several special considerations apply approach vaccination treatment practice transplantation also been heavily impacted by pandemic, including persistent reductions living donor increases an indication alcohol-related disease. Recent medical society guidelines strive standardize severe acute respiratory syndrome 2 testing donors recipients after recovered from infection, but certain controversies remain.

Language: Английский

Citations

4
COVID‐19 in organ donors: An organ procurement organization perspective DOI
Alyssa Mezochow, Judith A. Anesi, Sharon West

et al.

Transplant Infectious Disease, Journal Year: 2024, Volume and Issue: 26(2)

Published: Jan. 8, 2024

Abstract Background The COVID‐19 pandemic presented a significant challenge for Organ Procurement Organizations (OPOs) with the use of SARS‐CoV‐2 positive donors varying widely. This study used detailed single OPO data to determine success using donors. Methods We performed retrospective cohort including all referred Gift Life from January 1, 2021, June 30, 2023. Descriptive analyses were characterize referral and organ utilization. Results There 861 referrals 1 SARS‐Cov‐2 test: 282 ruled out telephone evaluation, 431 onsite evaluation (“evaluated nondonors”) 148 became For who had both nasopharyngeal lower respiratory testing completed, there was notable result discordance observed. Median cycle threshold (Ct) values similar between evaluated nondonors no change in median donor Ct over period. Transplanted organs COVID‐positive included 27 hearts, 88 livers, 5 pancreata, 107 kidneys; lung donation occurred. proportion significantly increased Conclusion large volume demonstrates increasing progressing time, supporting these nonlung transplantation. image

Language: Английский

Citations

1
Perspectives on donor‐derived infections from Germany DOI

Ana Paula Barreiros,

Klaus Böhler,

Kerstin Mönch

et al.

Transplant Infectious Disease, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 23, 2024

Often, organ transplantation is the only option to improve life expectancy and quality of patients with terminal failure. Despite improved donor assessment, a residual risk remains for transmitting infection, tumor, or other disease from recipients. Analysis, reporting, managing donor-derived diseases through vigilance surveillance system (V&S) mandatory in many countries. We report on suspected proven/probable infections (DDI) Germany over period 8 years (2016-2023).

Language: Английский

Citations

1
Utilization of COVID-19 positive donors for heart transplantation and associated short-term outcomes DOI Creative Commons
Ersilia M. DeFilippis, Brian Wayda, Anuradha Lala

et al.

The Journal of Heart and Lung Transplantation, Journal Year: 2022, Volume and Issue: 42(5), P. 651 - 659

Published: Dec. 11, 2022

Language: Английский

Citations

5
OPTN required SARS‐CoV‐2 lower respiratory testing for lung donors: Striking the balance DOI

Sarah E. Booker,

Courtney Jett,

Cole Fox

et al.

Transplant Infectious Disease, Journal Year: 2023, Volume and Issue: 25(3)

Published: March 2, 2023

Language: Английский

Citations

2
One Year Outcomes Following Transplantation with COVID-19-Positive Donor Hearts: A National Database Cohort Study DOI Creative Commons
Stanley B. Wolfe, Ruby Singh, Dane C. Paneitz

et al.

Journal of Cardiovascular Development and Disease, Journal Year: 2024, Volume and Issue: 11(2), P. 46 - 46

Published: Jan. 31, 2024

The current understanding of the safety heart transplantation from COVID-19+ donors is uncertain. Preliminary studies suggest that transplants these may be feasible. We analyzed 1-year outcomes in donor recipients using 1:3 propensity matching. OPTN database was queried for adult transplant between 1 January 2020 and 30 September 2022. were defined as those who tested positive on NATs or antigen tests within 21 days prior to procurement. Multiorgan transplants, retransplants, without COVID-19 testing, allocated under old allocation system excluded. A total 7211 met inclusion criteria, including 316 recipients. Further, 290 matched 870 COVID-19- Survival similar groups at (

Language: Английский

Citations

0
Effect of the opioid crisis on the liver transplantation donor pool: A national analysis DOI
Yutaka Endo, Kazunari Sasaki, Muhammad Musaab Munir

et al.

Clinical Transplantation, Journal Year: 2024, Volume and Issue: 38(4)

Published: March 28, 2024

Abstract Background Over the last decade there has been a surge in overdose deaths due to opioid crisis. We sought characterize temporal change donor (OD) use liver transplantation (LT), as well associated post‐LT outcomes, relative COVID‐19 era. Methods LT candidates and donors listed between January 2016 September 2022 were identified from Scientific Registry of Transplant Recipients database. Trends changes related OD assessed pre‐ versus post‐COVID‐19 (February 2020). Results Between 2022, most counties United States experienced an increase overdose‐related ( n = 1284, 92.3%) with many 458, 32.9%) having more than doubling drug deaths. Concurrently, was 11.2% overall donors, including 41.7% number who died overdose. In pre‐COVID‐19 4th top mechanism death, while era, 2nd common cause death. younger (OD: 35 yrs, IQR 29–43 vs. non‐OD: 43 31–56), had lower body mass index (≥35 kg/cm 2 , OD: 31.2% 33.5%), likely be HCV+ 28.9% 5.4%) total bilirubin (≥1.1 mg/dL, 12.9% 20.1%) (all p < .001). Receipt not worse graft survival (HR .94, 95% CI .88–1.01, .09). Conclusions Opioid markedly increased following pandemic, substantially altering pool States.

Language: Английский

Citations

0